Abstract Congenital polycythemias have diverse etiologies, including mutations in the hypoxia sensing pathway. These include HIF2A at exon 12, VHL gene (Chuvash polycythemia), and PHD2 mutations, which in one family was also associated with recurrent pheochromocytoma/paraganglioma (PHEO/PGL). Over the past two decades, we have studied seven unrelated patients with sporadic congenital polycythemia who subsequently developed PHEO/PGL with, until now, no discernible molecular basis. We now report a polycythemic patient with a novel germline HIF2A F374Y (exon 9) mutation, inherited from his mother, who developed PHEO/PGL. We show that this is a gain-of-function mutation and demonstrate no loss-of-heterozygosity or additional somatic mutation of HIF2A in the tumor, indicating HIF2A F374Y may be predisposing rather than causative of PHEO/PGL. This report, in view of two other concomitantly reported PHEO/PGL patients with somatic mutations of HIF2A and polycythemia, underscores the PHEO/PGL-promoting potential of mutations of HIF2A that alone are not sufficient for PHEO/PGL development.
Introduction
Elevated hemoglobin concentration is variably termed polycythemia or erythrocytosis. Based on the clinical history, polycythemias are divided into acquired and congenital categories [1] . In many instances, the principal cause is an elevated level of erythropoietin (EPO) [1, 2] . Hypoxia is a crucial stimulus for EPO production. One group of congenital polycythemias results from germline mutations of the hypoxia sensing pathway.
Studies of hypoxic regulation of EPO led to the discovery of the master hypoxia transcription factor, HIF-1 [3] . Polycythemia associated with mutations in the hypoxia sensing pathway includes dominantly inherited gain-of-function mutations of HIF-2-alpha (HIF2A), all found in exon 12.
There are also polycythemia-associated mutations of negative regulators of HIFs [4] , such as VHL R200W and VHL HIFs are transcription factors, dimers composed of hypoxia-inducible α subunits (HIF-1α, HIF-2α, and HIF-3α [10] ) and the constitutively expressed β subunit, and are the key regulators of the hypoxia response pathway. In the presence of oxygen, α subunits are hydroxylated by PHDs and then interact with pVHL, which leads to ubiquitination and a rapid degradation in proteasome [11] . HIF2 rather than HIF1 is the principal regulator of EPO gene transcription [12] and HIFs also augment erythropoiesis by EPOindependent mechanism(s) [13, 14] .
HIFs control vital functions via regulation of many functions and an array of genes [15] , and HIFs' augmentation is responsible for the Warburg effect [15, 16] , a unique feature of cancer metabolism. Germline and somatic mutations in the HIF pathway are a foundation of VHL tumor predisposition syndrome [17] [18] [19] that includes predisposition for PHEO/PGL. Typically, VHL syndrome is associated with dominantly inherited mutations of the VHL gene, with a germline loss-of-function mutation of one allele and an acquired somatic mutation of the VHL allele in trans. In many instances, such as VHL syndrome, upregulated HIFs are tumor promoter genes, but in some contexts, HIFs can also have a role as tumor suppressors [20] . However, mutations of other PHEO/PGL-associated genes in the HIF pathway do not have associated polycythemia phenotype.
Materials and methods
Samples and screening for mutation Propositus' blood and his mother's, and propositus' tumor were obtained with IRB approval, mRNA and gDNA extracted. Tumor and blood gDNA were subjected for PCR; likewise, propositus tumor's mRNA was reverse transcribed, amplified, and were sequenced for mutation.
Multiple sequence alignment of HIF-2α Set sequences of HIF2α from six species were aligned (Genetyx v8.0, Shibuya, Japan).
Computational analysis The structure of the HIF-2α F374Y mutation was investigated using computational proteinprotein docking and molecular dynamics (MD) simulations. The published HIF-2α X-ray structure [21] (PDB ID: 1P97-sequence 241-350) was used. A homology model was built using ICM modeling for remaining residues 351-375 (DVVFSMDQTESLFKPHLMAMNSIF), where HIF-2α F374Y is located. Molecular mechanics-based MMFF charges loop sampling and global energy optimization was performed. Docking against the crystal structure of the pVHL-ElonginBElonginC (VBC) complex bound to the 20-residue destruction sequence of HIF-1α (PDB ID: 1LQB) was utilized. ICM Optimal Docking Area (ODA) method [22] was used to predict the optimal surface with the lowest docking desolvation energy, -23.25 kcal/mol for the VBC structure.
HIF-2α protein stability assay Stability of HIF-2α F374Y was measured as described in article by Zhuang et al. [23] . In brief, HeLa cells were transfected with HIF2A F374Y vectors by Lipofectamine 2000 transfection reagent (Invitrogen). Medium was changed 4 h after transfection and cells were maintained 48 h before cycloheximide (20 μg/mL, Sigma-Aldrich) treatment. Cell lysate was resolved on NuPAGE Bis-Tris gel (Invitrogen), transferred to PVDF membrane (Millipore), and blotted with V5 antibody (Origene). HIF-2α protein residue was quantified through densitometric analysis.
Immunoprecipitation assay HIF-2α ubiquitination and VHL binding was determined through immunoprecipitation assay as previously described [23] HIF2Α or HIF2Α F374Y plasmids were co-transfected with Flag-tagged VHL plasmid into HeLa cells using Lipofectamine 2000 (Invitrogen). Cells were treated with MG-132 for 2 h (30 μM, EMD Millipore) before harvest. Cells were lysed in either NP40 lysis buffer for VHL binding or RIPA lysis buffer supplemented with 1 % SDS for HIF-2α ubiquitination assay. Lysate were immunoprecipitated using Dynabeads co-immunoprecipitation kit (Invitrogen) and anti-V5 antibody (Origene). Bound protein was eluted in loading buffer supplemented with 1 % SDS. Sample lysate were subsequently analyzed by western blot.
Reverse transcription and gene expression RNA from patient's tumor and three normal adrenal tissues were reverse transcribed using SuperScript VILO (Life Technology) and analyzed by hydrolysis probes (Applied Biosystem, Life Technology). The amount of each target mRNA was normalized using PPIA and GUSB mRNA using geNorm Plus (Biogazelle, Zwijnaarde, Belgium) in determining the most stable reference gene.
Copy number assay Copy number determination for EGLN1 and VHL genes were carried out using the propositus' and his mother's blood gDNA and propositus' tumor DNA and compared with three unaffected controls. Taqman hydrolysis probe (Applied Biosystem, Life Technology) for quantifying EGLN1 and VHL copy number were normalized using RNAse P as endogenous reference gene; samples were done in quadruplicate and run in two separate experiments.
Results and discussion
The propositus is a 50-year-old male, polycythemic with high EPO documented since early childhood (Hb 22.4 g/ dL, red cell mass 5,338 mL, 69 mL/kg) and treated by phlebotomies. At age 35, he developed high blood pressure and elevated urine norepinephrine. A lesion was found at the organ of Zuckerkandl; the tumor was removed and PGL was found. His catecholamines normalized; however, EPO remained elevated. Two years later, on a routine follow-up, a new lesion was found in the paraaortic region, and thoracic masses were detected again but patient was asymptomatic. At age 47, he developed recurrence of adrenergic symptoms with elevated norepinephrine and new vertebral, paraaortic region, celiac axis, and supramesenteric axis lesions found, with 68 Ga Octreotate PET/CT uptake and he remained asymptomatic. He underwent 131 I-metaiodobenzylguanidine therapy; his urine catecholamine normalized, but plasma normetanephrine, Hb%, and EPO remain elevated.
His 83-year-old mother agreed to genetic testing but initially refused to give further information. On subsequent request, she granted us a permission to access only her laboratory data available which included hemoglobin 148 g/L (normal range, 110-160) hematocrit 0.44 (normal range, 0.35-0.47) white blood count 4.8×10 9 /L (normal range, 4-11) platelets 180 × 10 9 /L (normal range, 150-450), and normal iron studies. While these results are within normal range, it should be noted that prevalence of anemia in this population is reported to exceed 30 % and in our experience we have encountered several examples wherein an initial testing for polycythemia was negative in the affected person only to be repeatedly positive in subsequent testing; we have published one such example [24] .
Mutation screening His 83-year-old mother agreed to genetic testing but refused to give further information. Blood gDNA Fig. 1 a-c HIF2A mutation screening and structural modeling analysis. a Sanger sequence of the blood and tumor tissue gDNA and cDNA. b Alignment of the HIF-2α amino acid sequence from 361 to 379 showing F374 residue in human against other known species. c Computational insight into HIF-2α F374Y mutation by Optimal Docking and Molecular Dynamic Studies. Y374 mutation-structural changes at the Pro103, Gly104 ND Thr105 site of pVHL β domain and exhibit significant conformational changes both at the β domain and ElonginC Ser87, Thr88, and Glu89 site (significant conformational changes can be observed mainly at ElonginC) of the propositus and mother and PGL tissue gDNA and cDNA had a heterozygous missense mutation NM_001430: c.1121T>A at exon 9, codon 374 (HIF2A F374Y ) (Fig. 1a) . These results rule out loss-of-heterozygosity as a contributing cause of PGL genesis. We have previously not encountered this HIF2A F374Y mutation in screening referred to us with unexplained congenital polycythemia (>30 at Baylor College of Medicine in Houston and 17 polycythemic and 41 normal controls at University of Utah). NCBI dbSNP database search reveal a HIF2A SNP variant of the codon (F374Y) was reported as rs150797491 in an ESP cohort sequencing with a minor allele frequency of the mutant allele at 0.1% observed twice in the population of 2276 (or 4552 chromosomes). No clinical data available. Other genes of the HIF pathway (EGLN1/PHD2, VHL, SDHB, SDHC, SDHD) and those causing polycythemia by different mechanisms (JAK2, EPOR, α,β-globins) had no mutations.
Multiple sequence alignment Multiple sequence alignment of HIF-2α protein was performed and F374 was found to be highly conserved among man, chimpanzee, mouse, horse, cattle, chicken, and zebrafish (Fig. 1b) , suggesting this serves an important function.
Molecular dynamics simulation To further test HIF-2α
F374Y protein function, simulated structural analysis and molecular dynamics were performed using the HIF-2α F374Y to determine residue binding site identified for ODA [22, 25] , which was predicted at the Pro103, Gly104, and Thr105 hairpin loop region of b domain of pVHL (Fig. 1c) . To define the overall effects of the HIF-2α F374Y mutation, MD simulations of ElonginB-ElonginC (VBC-HIFs-a degradation pathway) in complex with HIF-2α F374Y model was performed and it confirmed that HIF-2α F374Y causes conformational changes at Pro103, Gly104, and Thr105 sites of analyzed by immunoprecipitation assay. d Quantitative gene expression ratio of tumor to normal tissue of HIF and some target genes by qPCR. qPCR assay consist of two tumors and three normal adrenal tissues of two independent experiments assayed in duplicates pVHL b domain and exhibited significant changes at ElonginC Ser87, Thr88, and Glu88 contact sites (Fig. 1c ). This suggests a potential model of functional effect of HIF-2α F374Y to be the impairment of ElonginC interaction leading to gain-of-function of HIF-2α.
Stability of mutant HIF-2α
We determined the stability of HIF-2α F374 using cycloheximide treatment. Wild-type HIF2α protein had an 11.3-min lifespan. In contrast, HIF-2α F374 was more stable, with a half-life of 51.2 min (Fig. 2a, b) . To further examine the HIF-2α F374 signaling, we investigated the HIF-2α VHL binding and ubiquitination. After incubating Histagged HIF-2α proteins with VHL, comparable immunoprecipitation was performed with an anti-HA antibody, as shown in the middle blot (Fig. 2c) . This shows that the mutant HIF-2α protein has decreased binding to VHL protein and was less efficiently ubiquitinated compared to wild-type HIF-2α (Fig. 2c) . This further indicates that HIF-2α
F374 results in its gain-of-function with decreased E3 ligase binding and delayed proteasomal degradation.
Real-time PCR We analyzed the activity of hypoxia-related pathway by quantifying HIF-regulated genes expressed in the tumor. We found marked upregulation of GLUT1 and VEGFA and downregulation of EDN1 transcript (Fig. 2d) , consistent with HIF2Α gain-of-function mutation. Structural variation within the gene such as copy number can influence gene expression and be associated with specific phenotype, despite normal sequence of the EGLN1 and VHL genes. Thus, we further evaluated the copy number of these two genes and both genes were diploid in both tumor and germline DNA. These data were identical to concomitantly tested three controls that were analyzed at the same time. These data indicate that the copy number of variations of EGLN1 and VHL gene were not contributory to the phenotype we observed in the propositus. This is the first report of a germline gain-of-function EPAS1/HIF2A mutation associated with congenital polycythemia that is also associated with multiple PGL tumors. Unlike other HIF2A genes that are located in exon 12, the HIF2A F374 mutation is located in a uniquely conserved site at exon 9. We found no evidence of HIF2A loss-of-heterozygosity, additional mutations of HIF2A in tumor tissue, or copy number variations in both germline and tumor DNAs. This is in contrast to that found in von Hippel-Lindau PHEO/PGL syndrome and in a family with polycythemia and PHEO/ PGL associated with a PHD2 mutation [25] . However, the failure to find polycythemia in propositus' mother whose blood counts were at the time of testing at her age of 83 years within normal range is not in keeping with this mutation being fully penetrant for polycythemia phenotype. It should be noted that prevalence of anemia in her age group is reported to exceed 30 % that can obscure the polycythemia phenotype. Further, in our experience, we have encountered several examples wherein an initial evaluation for polycythemia phenotype was negative in the affected person bearing dominantly inherited polycythemia-causing gene and only to be repeatedly positive in subsequent evaluations. Indeed, we previously published one such an example [24] .
The fact that two unrelated, concomitantly reported PHEO/PGL patients with polycythemia who had somatic mutations in tumor tissues of HIF2A, albeit at different locations than HIF2A F374 (G1588A and C1589T exon 12 [23] ), underscores the PHEO/PGL-promoting potential of gain-of-function mutations of HIF2A that alone, either as somatic or germline mutations, can contribute to but are not sufficient for PHEO/PGL development.
